Jump Financial LLC Acquires Shares of 25,300 Fulgent Genetics, Inc. (NASDAQ:FLGT)

Jump Financial LLC bought a new position in Fulgent Genetics, Inc. (NASDAQ:FLGT) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 25,300 shares of the company’s stock, valued at approximately $467,000. Jump Financial LLC owned approximately 0.08% of Fulgent Genetics as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently made changes to their positions in FLGT. JPMorgan Chase & Co. increased its holdings in shares of Fulgent Genetics by 113.2% during the third quarter. JPMorgan Chase & Co. now owns 338,044 shares of the company’s stock valued at $7,346,000 after acquiring an additional 179,477 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in Fulgent Genetics by 803.2% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 125,957 shares of the company’s stock valued at $2,326,000 after purchasing an additional 112,011 shares in the last quarter. Inlight Wealth Management LLC purchased a new position in Fulgent Genetics in the fourth quarter worth about $685,000. Intech Investment Management LLC lifted its stake in shares of Fulgent Genetics by 248.3% in the fourth quarter. Intech Investment Management LLC now owns 43,539 shares of the company’s stock worth $804,000 after buying an additional 31,037 shares in the last quarter. Finally, Proficio Capital Partners LLC purchased a new stake in shares of Fulgent Genetics during the fourth quarter valued at approximately $411,000. Hedge funds and other institutional investors own 48.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on FLGT. Piper Sandler lowered their price objective on Fulgent Genetics from $22.00 to $16.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. StockNews.com raised shares of Fulgent Genetics from a “sell” rating to a “hold” rating in a report on Wednesday, March 5th.

Fulgent Genetics Stock Up 0.7 %

NASDAQ FLGT opened at $19.04 on Friday. The company has a 50-day moving average price of $17.26 and a 200-day moving average price of $18.16. Fulgent Genetics, Inc. has a 52 week low of $14.57 and a 52 week high of $25.11. The firm has a market capitalization of $587.69 million, a P/E ratio of -3.45 and a beta of 1.36.

Insider Buying and Selling at Fulgent Genetics

In related news, CFO Paul Kim purchased 100,000 shares of the business’s stock in a transaction on Wednesday, March 5th. The stock was acquired at an average price of $15.96 per share, with a total value of $1,596,000.00. Following the completion of the acquisition, the chief financial officer now owns 348,282 shares of the company’s stock, valued at approximately $5,558,580.72. This trade represents a 40.28 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 31.76% of the stock is owned by corporate insiders.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.